Table 4.
Results from RCT and RWE scenarios
| T1D | T2D | |||||
|---|---|---|---|---|---|---|
| Flash monitoring | SMBG/POCT | Incremental | Flash monitoring | SMBG/POCT | Incremental | |
| RCT scenario results | ||||||
| Costs (CNY) | 1,098,593 | 1,040,572 | 58,021 | 497,054 | 406,057 | 90,997 |
| Direct costs | 901,253 | 791,555 | 109,698 | 497,054 | 406,057 | 90,997 |
| Intervention | 288,159 | 134,341 | 153,818 | 209,996 | 88,028 | 121,968 |
| Disease monitoring | 3605 | 3407 | 198 | 3422 | 3359 | 63 |
| Chronic complications | 482,569 | 450,040 | 32,529 | 217,520 | 213,000 | 4520 |
| Acute events | 126,919 | 203,765 | − 76,846 | 66,116 | 101,669 | − 35,553 |
| Indirect costs* | 197,340 | 249,017 | − 51,677 | – | – | – |
| LYs | 14.76 | 13.92 | 0.84 | 10.78 | 10.60 | 0.18 |
| QALYs | 9.20 | 7.98 | 1.22 | 6.87 | 6.22 | 0.65 |
| ICER (CNY/QALY) | – | – | 47,636 | – | – | 140,297 |
| RWE scenario results | ||||||
| Costs (CNY) | 1,040,864 | 1,042,582 | − 1718 | 495,167 | 408,907 | 86,261 |
| Direct costs | 847,675 | 780,404 | 67,271 | 495,167 | 408,907 | 86,261 |
| Intervention | 290,631 | 134,776 | 155,855 | 210,319 | 87,819 | 122,500 |
| Disease monitoring | 3736 | 3443 | 293 | 3426 | 3350 | 76 |
| Chronic complications | 425,419 | 437,663 | − 12,244 | 215,283 | 216,269 | − 986 |
| Acute events | 127,890 | 204,523 | − 76,633 | 66,140 | 101,469 | − 35,329 |
| Indirect costs* | 193,189 | 262,177 | − 68,989 | – | – | – |
| LYs | 14.90 | 13.97 | 0.93 | 10.80 | 10.57 | 0.23 |
| QALYs | 9.31 | 8.00 | 1.32 | 6.89 | 6.20 | 0.70 |
| ICER (CNY/QALY) | – | – | Dominant | – | – | 124,169 |
CNY Chinese yuan, SMBG/POCT self-monitoring of blood glucose, T1D type 1 diabetes, T2D type 2 diabetes, LY life year, QALY quality-adjusted life year, ICER incremental cost-effectiveness ratio
*As the baseline age of patients with T2D was older than the retirement age in China, no indirect costs were calculated for T2D from the societal perspective